Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?

Journal of Surgical Oncology

Volumn 105, Issue 1, 2012, Pages 55-59

  Reddy, Srinevas K ^a   Tsung, Allan ^a   Marsh, James Wallis ^a   Geller, David A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Chemotherapy; Colorectal cancer liver metastases; Neoadjuvant

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; COLORECTAL CANCER; COLORECTAL CANCER LIVER METASTASIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83555164958     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22044     Document Type: Article

References (32)

1. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016. (Pubitemid 351392040)
2. Vauthey JN, Nordlinger B, Kopetz S, et al.: Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: A debate over goals of research and an approach while the jury remains out. Ann Surg Oncol 2010; 17: 1983-1986.
3. Reddy SK, Barbas AS, Clary BM,: Synchronous colorectal liver metastases: Is it time to reconsider traditional paradigms of management? Ann Surg Oncol 2009; 16: 2395-2410.
4. Power DG, Kemeny NE,: Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 2010; 28: 2300-2309.
5. Nordlinger B, Van Custem E, Gruenberger T, et al.: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: Recommendations from an expert panel. Ann Oncol 2009; 20: 985-992.
6. Rubbia-Brandt L,: Sinusoidal obstruction syndrome. Clin Liver Dis 2010; 14: 651-668.
7. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072. (Pubitemid 46622116)
8. Aloia T, Sebagh M, Plasse M, et al.: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990. (Pubitemid 46631400)
9. Tamandl D, Klinger M, Epideldauer S, et al.: Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2010; 18: 421-430.
10. Ryan P, Nanji S, Pollett A, et al.: Chemotherapy-induced liver injury in metastatic colorectal cancer: Semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010; 34: 784-791.
11. Brouquet A, Benoist S, Julie C, et al.: Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009; 145: 362-371.
12. Morris-Stiff G, Tan YM, Vauthey JN,: Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal liver metastases. Eur J Surg Oncol 2008; 34: 609-614. (Pubitemid 351671976)
13. Pawlik TM, Olino K, Gleisner AL, et al.: Preoperative chemotherapy for colorectal liver metastases: Impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868.
14. Fernandez FG, Ritter J, Goodwin JW, et al.: Effect of steatohepatitis associated with irinotecan or oxaliplatin on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-863.
15. Karoui M, Penna C, Amin-Hashem M, et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7. (Pubitemid 43054046)
16. Carpenter S, Fong Y,: Management of disappearing colorectal hepatic metastases. Adv Surg 2010; 44: 269-279.
17. Adam R, Wicherts DA, de Haas RJ, et al.: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 2008; 26: 1635-1641.
18. Benoist S, Brouquet A, Penna C, et al.: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006; 24: 3939-3945. (Pubitemid 46630742)
19. van Vledder MG, de Jong MC, Pawlik TM, et al.: Disappearing colorectal liver metastases after chemotherapy: Should we be concerned? J Gastrointest Surg 2010; 14: 1691-1700.
20. Elias D, Goere D, Boige V, et al.: Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: Impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194. (Pubitemid 47594272)
21. Charnsangavej C, Clary B, Fong Y, et al.: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1261-1268. (Pubitemid 44435791)
22. Blazer DG, Kishi Y, Maru DM, et al.: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 25: 5344-5351.
23. Gruenberger B, Tamandl D, Scheuller J, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
24. Gruenberger B, Scheithauer W, Punzengruber R, et al.: Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008; 8: 120-126.
25. Reddy SK, Zorzi D, Lum YW, et al.: Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann Surg Oncol 2009; 16: 1809-1819.
26. Adam R, Bhangui P, Poston G, et al.: Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010; 252: 774-787.
27. Pawlik TM, Assumpcao L, Vossen JA, et al.: Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol 2009; 16: 371-378.
28. Strasberg SM, Dehdashti F,: Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer. J Surg Oncol 2010; 102: 955-959.
29. Orlacchio A, Schillaci O, Fusco N, et al.: Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med 2009; 114: 571-585.
30. Yang YY, Fleshman JW, Strasberg SM, et al.: Detection and management of extrahepatic colorectal cancer in patients with resectable liver metastases. J Gastrointest Surg 2007; 11: 929-944.
31. Kong G, Jackson C, Koh DM, et al.: The use of 18F-FDG-PET/CT in colorectal liver metastases-Comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008; 35: 1323-1329.
32. Rappeport ED, Loft A, Berthelsen AK, et al.: Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: A prospective study with intraoperative confirmation. Acta Radiol 2007; 48: 369-378. (Pubitemid 46633866)